Seegene, Inc. (KOSDAQ:096530)
South Korea
· Delayed Price · Currency is KRW 26,550
+250 (0.95%)
May 2, 2025, 3:30 PM KST
Seegene Revenue
In the year 2024, Seegene had annual revenue of 414.25B KRW with 12.76% growth. Seegene had revenue of 115.34B in the quarter ending December 31, 2024, with 14.75% growth.
Revenue
414.25B
Revenue Growth
+12.76%
P/S Ratio
2.96
Revenue / Employee
6.58B
Employees
63
Market Cap
1,225.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 414.25B | 46.88B | 12.76% |
| Dec 31, 2023 | 367.38B | -486.19B | -56.96% |
| Dec 31, 2022 | 853.56B | -517.27B | -37.73% |
| Dec 31, 2021 | 1,370.83B | 245.62B | 21.83% |
| Dec 31, 2020 | 1,125.22B | 1,003.26B | 822.66% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| PharmaResearch | 350.12B |
| Peptron | 3.15B |